AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

RecruitingPhase 3Ages 18 Years - anyAllCentre Hospitalier Universitaire de Saint Etienne
💬

In plain words

What the trial is, and whether it could suit you

Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease share common risk factors and frequently coexist in the same patients. Their management requires use of antithrombotic agents: anticoagulant therapy (AC) for secondary prevention of VTE recurrence, antiplatelet (AP) for secondary prevention of major adverse ischemic cardiovascular and cerebrovascular event (MACCE) in patients with atherosclerotic cardiovascular disease (coronary artery disease, atherosclerotic cerebrovascular disease, lower extremity peripheral arterial disease). Side effects of antithrombotic drugs are the 1st cause of emergency admission and hospitalization for an adverse drug reaction (mainly bleeding), and the combination of AC with AP strongly increases this risk.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion criteria * Signed informed consent * Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis). Proximal deep-vein thrombosis is defined as thrombosis involving at least the popliteal vein or a more proximal vein of the lower limb. * Indication of full-dose anticoagulant therapy for at least 3 months. * Prescription of antiplatelet therapy for secondary prevention of atherosclerotic cardiovascular diseases, at the time of VTE diagnosis * Life expectancy more than 3 months * Social security affiliation Exclusion Criteria: * Unable to give informed consent * Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg * Anticoagulation for more than 5 days prior to randomization * Active pregnancy or expected pregnancy or no effective contraception * Isolated distal deep vein thrombosis * Antiplatelet therapy prescribed for primary prevention of cardiovascular disease * Indication to maintain a dual-antiplatelet therapy. * Triple positive antiphospholipid syndrome, with arterial thrombosis * Major cardiovascular and cerebrovascular event in the past 12 months for acute coronary syndrome, and in the past 6 months for cerebrovascular diseases and peripheral arterial diseases
💊

What it tests

  • Full-dose anticoagulant therapy (AC)
  • Antiplatelet therapy (AP)
📍

Where

28 sites
CHU Amiens
Amiens, France
CHU Angers
Angers, France
CHU Besançon - Hôpital Jean Minjoz
Besançon, France
CHRU Brest - Hôpital la Cavale Blanche
Brest, France
Clinique du Parc - Castelnau-le -lez
Castelnau-le-Lez, France
CHU Clermont-Ferrand - Hôpital Gabriel Montpied
Clermont-Ferrand, France
CHU Dijon
Dijon, France
CH le Corbusier - Firminy
Firminy, France

…and 20 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy